Omnicell (OMCL) Stock Overview
Provides healthcare technology in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for OMCL from our risk checks.
OMCL Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Omnicell, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.63 |
| 52 Week High | US$55.00 |
| 52 Week Low | US$29.06 |
| Beta | 0.97 |
| 1 Month Change | -12.52% |
| 3 Month Change | -15.25% |
| 1 Year Change | 0.96% |
| 3 Year Change | -40.52% |
| 5 Year Change | -78.91% |
| Change since IPO | 243.11% |
Recent News & Updates
Seeking Alpha • Aug 25
Omnicell: Offers Good Value, But Uncertainty Remains
Summary Omnicell, which is down by -24% on a YTD basis, has also underperformed other medtech and small-cap healthcare stocks by a large margin. OMCL faces near-term headwinds, with YoY revenue contraction for the first time in seven quarters and increased uncertainty around product bookings for FY26. OMCL's sales cycle for its new-gen Titan XT system remains slow amid heightened competition and a lack of alacrity to upgrade from old-gen systems. Gross margins in H2 are going to be pressured by memory chip shortages, leading to higher sourcing costs and a projected 50 bps margin hit in FY26. However, the weakness in the stock price has also made the stock emerge as one of the strong value bets within the small-cap healthcare universe. Read the full article on Seeking Alpha
Narrative Update • Aug 14
OMCL: Aging Systems And Pipeline Conversion Will Drive Higher Future Earnings Multiple
Analysts have trimmed their Omnicell price targets to a range centered around $45, citing a shift to a $45 fair value estimate from $50, even as they highlight strong recent results and note that the company’s pipeline and aging installed base could support bookings over time. Analyst Commentary on Omnicell Recent research commentary on Omnicell points to a mixed picture.Narrative Update • Jul 31
OMCL: Aging Systems And Pipeline Conversion Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Omnicell stock to $50 from $55, citing expectations that shares may stay range bound until the company’s pipeline converts into bookings and aging installed systems drive more urgent replacement demand. What’s in the News for Omnicell Omnicell issued earnings guidance for the third quarter of 2026 with expected total revenue in a range of US$301 million to US$307 million.Recent updates
Seeking Alpha • Aug 25
Omnicell: Offers Good Value, But Uncertainty Remains
Summary Omnicell, which is down by -24% on a YTD basis, has also underperformed other medtech and small-cap healthcare stocks by a large margin. OMCL faces near-term headwinds, with YoY revenue contraction for the first time in seven quarters and increased uncertainty around product bookings for FY26. OMCL's sales cycle for its new-gen Titan XT system remains slow amid heightened competition and a lack of alacrity to upgrade from old-gen systems. Gross margins in H2 are going to be pressured by memory chip shortages, leading to higher sourcing costs and a projected 50 bps margin hit in FY26. However, the weakness in the stock price has also made the stock emerge as one of the strong value bets within the small-cap healthcare universe. Read the full article on Seeking AlphaNarrative Update • Aug 14
OMCL: Aging Systems And Pipeline Conversion Will Drive Higher Future Earnings Multiple
Analysts have trimmed their Omnicell price targets to a range centered around $45, citing a shift to a $45 fair value estimate from $50, even as they highlight strong recent results and note that the company’s pipeline and aging installed base could support bookings over time. Analyst Commentary on Omnicell Recent research commentary on Omnicell points to a mixed picture.Narrative Update • Jul 31
OMCL: Aging Systems And Pipeline Conversion Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Omnicell stock to $50 from $55, citing expectations that shares may stay range bound until the company’s pipeline converts into bookings and aging installed systems drive more urgent replacement demand. What’s in the News for Omnicell Omnicell issued earnings guidance for the third quarter of 2026 with expected total revenue in a range of US$301 million to US$307 million.
Narrative Update • Jul 06
OMCL: Cabinet Replacement Cycle Will Support Higher Multiple As New Leadership Executes
Omnicell's updated analyst price target has increased from $63 to $70. Analysts cited adjusted fair value, refined discount rate assumptions, and expectations for a higher future P/E multiple to support the change.Narrative Update • Jun 22
OMCL: Earnings Rebound And Guidance Will Support Higher Future Earnings Multiple
Analysts have nudged their price targets on Omnicell higher, with recent Street research pointing to modestly improved expectations that support a slightly richer long term fair value framework anchored around $55. Analyst Commentary Recent Street research on Omnicell reflects a mixed tone, with higher price targets framed within a cautious backdrop.Analysis Article • Jun 21
Omnicell (OMCL) Stock Could Be 36.3% Undervalued After Specialty Pharmacy Leadership Hire
Omnicell (OMCL) stock is back in focus after the company appointed veteran pharmacy operator Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, a move tied directly to its Specialty Pharmacy and 340B ambitions. See our latest analysis for Omnicell. Omnicell’s latest leadership change comes after a mixed stretch in the market, with the stock’s share price showing a 13.82% 90 day return but down 12.07% over 30 days, while the 1 year total shareholder return...
Narrative Update • Jun 04
OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Demand
Analysts have lifted their price target on Omnicell by $12 in total, supported by refreshed assumptions on discount rate, revenue growth, profit margin and future P/E. These changes leave the stock's fair value estimate broadly unchanged at about $61.29.Narrative Update • May 19
OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Upside
Analysts lifted the Omnicell price target by about $4, reflecting updated fair value estimates and revised assumptions on discount rate, revenue growth, profit margin, and future P/E multiples, supported by recent research from multiple firms. Analyst Commentary Recent Street research includes price target increases of about $2 and $10, which gives a sense of how bullish and cautious views are being weighed around Omnicell right now.Analysis Article • May 14
Omnicell's (NASDAQ:OMCL) Conservative Accounting Might Explain Soft Earnings
The market was pleased with the recent earnings report from Omnicell, Inc. ( NASDAQ:OMCL ), despite the profit numbers...Narrative Update • May 01
OMCL: New Product Cycle Will Reset Expectations And Support Higher Future Earnings Multiple
Analysts have reset their view on Omnicell, with the consolidated fair value estimate moving from $49.00 to $55.00. This reflects updated assumptions on discount rate, growth, margins and future P/E, alongside recent price target hikes and rating changes across the Street.Narrative Update • Apr 16
OMCL: New Product Cycle Will Drive Next Cabinet Super Cycle
Narrative Update on Omnicell Analysts now see a slightly lower blended price target for Omnicell, with recent moves spanning a $14 cut at one firm and a $10 increase at another. They are weighing a new product cycle against differing views on execution and risk.Narrative Update • Apr 01
OMCL: Cabinet Replacement Cycle Will Drive Future Super Cycle Repricing
Narrative Update on Omnicell The updated analyst price target for Omnicell has shifted by $14 as analysts balance recent upgrades tied to a new product cycle and cabinet replacement opportunity against a lower target from one firm, while keeping the model's fair value estimate steady at $49. Analyst Commentary Recent research on Omnicell presents a mixed picture, with some firms highlighting upside linked to a new product cycle and cabinet replacement opportunity, while more cautious voices are resetting expectations and price targets.Narrative Update • Mar 18
OMCL: Cabinet Replacement Cycle Will Drive Future Risk Reward Repricing
Analysts have trimmed the Omnicell fair value estimate from $50.00 to $49.00, reflecting slightly softer assumptions for revenue growth and profit margins, even as they factor in a higher future P/E multiple supported by recent upgrades tied to the new product cycle and cabinet refresh story. Analyst Commentary Recent Street research on Omnicell has been mixed, with some firms trimming price targets while others turn more constructive on the new product cycle and cabinet refresh opportunity.Narrative Update • Mar 04
OMCL: Cabinet Replacement Cycle Will Drive Future Medication Management Upside
Analysts have adjusted their Omnicell price target by $14, reflecting mixed research that includes both target cuts and upgrades related to expectations around the new product cycle and potential cabinet replacement demand. Analyst Commentary Bullish Takeaways Bullish analysts see the new Titan XT cabinets as a key product that could support higher long term growth expectations if hospitals move ahead with planned cabinet replacements.Narrative Update • Feb 18
OMCL: Cabinet Refresh Cycle Will Support Future Medication Management Upside
Analysts have nudged their fair value estimate for Omnicell higher from $51.50 to about $57.43, citing updated views on its product cycle and cabinet refresh opportunity as reflected in recent research. Analyst Commentary Recent research coverage on Omnicell reflects a mix of optimism around the new product cycle and cabinet refresh, alongside some restraint on how quickly that opportunity may translate into value.Analysis Article • Feb 12
Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge
The Omnicell, Inc. ( NASDAQ:OMCL ) share price has softened a substantial 26% over the previous 30 days, handing back...Narrative Update • Feb 04
OMCL: Cabinet Replacement Cycle Could Drive Upside In Concentrated Market
Analysts have raised their fair value estimate for Omnicell to US$63 from US$55, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. This change is supported by recent positive research on the potential impact of the Titan XT cabinet cycle and competitive wins.Narrative Update • Jan 21
OMCL: Cabinet Replacement Cycle Will Shape Future Risk Reward Balance
Narrative Update on Omnicell The analyst price target for Omnicell has moved from $43 to $50 as analysts point to potential cabinet replacement demand and the Titan XT launch as key drivers for expected improvements in sales, earnings, and valuation assumptions. Analyst Commentary Recent research highlights a more constructive tone around Omnicell, with some analysts pointing to a potential cabinet replacement cycle and the Titan XT launch as key themes in their work.Narrative Update • Jan 06
OMCL: Future Medication Management Platform Rollout Will Support Balanced Risk Reward Profile
Analysts have lifted their price target on Omnicell from US$34 to US$43, pointing to updated assumptions for slightly lower discount rates, firmer revenue growth, improved profit margins, and a more moderate future P/E outlook. What's in the News Omnicell launched Omnicell Titan XT, an enterprise version of its automated dispensing systems designed to unify automation with its cloud-based OmniSphere medication management platform, aiming to create a connected, enterprise-wide medication management ecosystem across care areas.Narrative Update • Dec 18
OMCL: New Medication Management Platform Will Support Future Upside Potential
Analysts have raised their price target on Omnicell from approximately 47.33 dollars to 51.50 dollars. This change reflects slightly lower perceived risk, modestly stronger long term profit margins, and a higher expected future earnings multiple.Narrative Update • Dec 04
OMCL: Share Repurchases Will Support Future Upside Potential
Analysts have modestly raised their price target on Omnicell to approximately $47.33 per share, reflecting slightly lower perceived risk and stable, long-term growth and profitability expectations. What's in the News Updated fourth quarter 2025 revenue guidance to a range of $306 million to $316 million, signaling stable near term demand (company guidance).Narrative Update • Nov 20
OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside
Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.Analysis Article • Nov 13
Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified
Omnicell, Inc. ( NASDAQ:OMCL ) shareholders would be excited to see that the share price has had a great month, posting...Narrative Update • Nov 06
OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position
Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.Analysis Article • Jul 16
Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Analysis Article • Jun 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Omnicell fair value estimate is US$40.16 Omnicell is estimated...New Narrative • May 27
Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges
Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.Analysis Article • May 14
It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights Omnicell's Annual General Meeting to take place on 21st of May CEO Randy Lipps' total compensation...Analysis Article • May 09
US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results
There's been a notable change in appetite for Omnicell, Inc. ( NASDAQ:OMCL ) shares in the week since its first-quarter...Analysis Article • Apr 07
Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Mar 20
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Omnicell, Inc. ( NASDAQ:OMCL ), is not the largest company out there, but it received a lot of attention from a...Analysis Article • Feb 14
Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Despite posting healthy earnings, Omnicell, Inc.'s ( NASDAQ:OMCL ) stock has been quite weak. Our analysis suggests...Seeking Alpha • Feb 12
Omnicell Q4 Earnings: Ignore The Short-Term Noise
Summary Omnicell's Q4 2024 earnings showed strong service revenue growth, despite soft overall revenue guidance, highlighting the service business as the key value driver. My updated DCF analysis yields a price target of $64.05, representing a 54% upside, and I raise my rating from buy to strong buy. The service business has grown from 6% to 22% of revenue since 2020, outpacing industry growth and improving margins, indicating long-term value. Downside risks include the need to balance service growth with product decline, but the healthy backlog mitigates these concerns, presenting a buying opportunity. Read the full article on Seeking AlphaAnalysis Article • Feb 09
Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a mediocre week for Omnicell, Inc. ( NASDAQ:OMCL ) shareholders, with the stock dropping 11% to US$40.16 in...Shareholder Returns
| OMCL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.7% | -3.6% | -1.5% |
| 1Y | 1.0% | -15.8% | 13.3% |
Return vs Industry: OMCL exceeded the US Medical Equipment industry which returned -15.8% over the past year.
Return vs Market: OMCL underperformed the US Market which returned 13.3% over the past year.
Price Volatility
| OMCL volatility | |
|---|---|
| OMCL Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: OMCL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OMCL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,485 | Randy Lipps | www.omnicell.com |
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services.
Omnicell, Inc. Fundamentals Summary
| OMCL fundamental statistics | |
|---|---|
| Market cap | US$1.53b |
| Earnings (TTM) | US$39.08m |
| Revenue (TTM) | US$1.25b |
38.1x
P/E Ratio1.2x
P/S RatioIs OMCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMCL income statement (TTM) | |
|---|---|
| Revenue | US$1.25b |
| Cost of Revenue | US$697.98m |
| Gross Profit | US$548.73m |
| Other Expenses | US$509.64m |
| Earnings | US$39.08m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.86 |
| Gross Margin | 44.01% |
| Net Profit Margin | 3.13% |
| Debt/Equity Ratio | 13.0% |
How did OMCL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/15 21:59 |
| End of Day Share Price | 2026/09/15 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Omnicell, Inc. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhilin Long | Berenberg |
| Allen Lutz | BofA Global Research |
| Eugene Mannheimer | B. Riley Securities, Inc. |